A 24-week prospective, open-label, multicenter study to evaluate the effect on seizure frequency, safety and tolerability of oxcarbazepine monotherapy in adult patients with partial seizures

Trial Profile

A 24-week prospective, open-label, multicenter study to evaluate the effect on seizure frequency, safety and tolerability of oxcarbazepine monotherapy in adult patients with partial seizures

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Oxcarbazepine (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 29 Nov 2007 Status changed from in progress to completed.
    • 27 Nov 2006 Status change
    • 27 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top